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ABSTRACT
Introduction: Clozapine is regarded as the most effective antipsychotics for patients with treatment-resistant schizophrenia. 
Of late cardiac safety becomes a principal concern including QTc prolongation that can lead to sudden cardiac death. 
Objective: This case report will highlight the development of clozapine-induced QTc prolongation, and subsequent stabiliza-
tion with combined aripiprazole and electroconvulsive therapy (ECT) in a patient with treatment-resistant schizophrenia.
Result: We reported a 30-year-old male patient with treatment-resistant schizophrenia who developed QTc prolongation. In 
2014, prolonged QTc 521ms was attributed to hypocalcemia. Then in 2016, prolonged QTc 492 ms was noted after the ECT, and 
most recently QTc 504 ms while on clozapine 100 mg daily. Other investigations including electrolytes, echocardiogram, thyroid, 
renal and liver function tests were normal. Subsequently, the patient was stabilized on combined aripiprazole and ECT. The 
QTc ranged 460 to 494 ms while he was on aripiprazole 15 mg daily.
Conclusion: The combined use of aripiprazole and ECT is safe for treatment of treatment-resistant schizophrenia with pro-
longed QTc. Close monitoring is recommended since QTc impact of aripiprazole may be additive to the arrhythmia risk.
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INTRODUCTION
To date clozapine is the most effective antipsychotic for patients 
with schizophrenia who are treatment resistant1,2). A systematic review 
and meta-analysis revealed a 40% response rate to clozapine2) and lower 
mortality rate among clozapine-treated individuals with treatment-resis-
tant schizophrenia compared to individuals not treated with clozapine3).
Of late cardiac safety becomes a principal concern as emerging data 
show second generation antipsychotics such as clozapine, contributed to 
the increased mortality due to the association with life-shortening meta-
bolic adverse effects, including weight gain, dyslipidemia, and type 2 
diabetes mellitus4,5). Additionally, cardiac adverse effects like myocardi-
tis6,7), pericarditis8,9), and cardiomyopathy10) had been reported as well.
Of particular interest is clozapine effect on QTc prolongation (> 450 
ms in males, > 470 ms in females) which put patients at risk for sudden 
cardiac death. Prolongation of ventricular action potential duration may 
result in polymorphic ventricular tachycardia termed torsade de pointes 
that can degenerate into ventricular fibrillation. A QTc values higher 
than 500 ms are strongly prolonged and linked with a clear risk of tor-
sade de pointes11).
However, QTc prolongation alone does not appear to explain tor-
sade de pointes; several other factors must be present simultaneously 
with QT prolongation before torsade de pointes occurs12). A systematic 
review of 10 observational studies with a total of 89,532 patients con-
cluded that risk factors for QTc prolongation evidence were very strong 
for hypokalemia and medication such as diuretics, antiarrhythmic drugs. 
The evidence was strong for age ≥ 65 years, female gender, smoking, 
ischemic cardiomyopathy, hypertension, arrhythmia, thyroid disturbanc-
es, hypocalcemia and use of ≥ 1 QTc-prolonging drugs11). 
This case report will highlight the development of clozapine-in-
duced QTc prolongation, and subsequent stabilization with combined 
aripiprazole and electroconvulsive therapy (ECT) in a patient with treat-
ment-resistant schizophrenia.
CASE  REPORT
A 30-year-old, single, unemployed gentleman with schizophrenia on 
oral clozapine 100 mg daily was admitted to psychiatric ward with audi-
tory hallucinations, grandiose delusions, insomnia, disorganized behav-
ior and irritability for 2 weeks duration in March 2017. It was noted that 
the patient had asymptomatic prolonged QTc 504 ms. Other investiga-
tions including electrolytes, echocardiogram, thyroid, renal and liver 
function tests were normal.
Due to the QTc prolongation, he was referred to medical and cardi-
ology team and was treated as prolonged QTc secondary to clozapine. 
The clozapine was then withheld and patient was restarted on aripipra-
zole which was optimized up to 15 mg daily. The patient showed 
improvement in the ward, however, he was readmitted again 2 weeks 
after discharge as he developed similar episode of auditory hallucina-
tions and disorganized behavior. For that admission he was started on 
acute ECT for 12 sessions in a closely monitored setting by anesthesia 
team while aripiprazole was continued at 15 mg daily. The patient 
showed tremendous improvement, thus fortnightly maintenance ECT 
   C   2018 Japan Health Sciences University
             & Japan International Cultural Exchange Foundation
Nordin M. F. et al.292
was planned. He was well and able to participate in occupational thera-
py activities. The QTc ranged 460 to 494 ms while he was on aripipra-
zole 15 mg daily. However, he received only 2 sessions of maintenance 
ECT and was lost to follow-up. 
Past psychiatric history revealed that the patient was diagnosed with 
schizophrenia 10 years before when he presented with auditory halluci-
nations, persecutory delusions, social withdrawal and poor self-hygiene 
of 6 months duration. He had been frequently admitted and treated with 
multiple psychotropic agents such as olanzapine up to 20 mg daily, que-
tiapine up to 600 mg daily, sulpiride 800mg daily, lithium 600 mg daily, 
intramuscular depot flupenthixol 40 mg monthly and aripiprazole up to 
15mg daily, however, patient did not show much improvement. He was 
then treated as a case of treatment resistant schizophrenia and started on 
clozapine, and the highest dose that he had ever been on was 500 mg 
daily. He was also given a few courses of acute electroconvulsive thera-
py (ECT). However, the clozapine regime had to be restarted a few 
times as the patient defaulted treatment once he felt better during peri-
ods of partial remission. He also had 2 episodes of prolonged QTc; in 
2014, 521 ms, which was attributed to low serum calcium level, 2.07 
mmol/L (normal value 2.2-2.6 mmol/L), during this time, patient 
defaulted treatment for more than a month prior to admission, and in 
2016, QTc was 435 ms on admission but was prolonged to 492 ms after 
4th session of acute ECT, patient at the time was on olanzapine 20mg 
daily which was started 2 months prior to the admission. For both of 
these episodes, the patient was referred to medical team for assessment.
DISCUSSION
In this patient, aripiprazole was chosen as it confers the lowest risk 
of QTc prolongation. A meta-analysis13) revealed that the QTc prolonga-
tion risk with aripiprazole was lower compared with placebo and other 
antipsychotics including chlorpromazine, clozapine, haloperidol, olan-
zapine, perospirone, perphenazine, quetiapine, risperidone, sulpiride, 
and ziprasidone, and thus concluded that aripiprazole has a low cardiac 
risk in healthy patients. Nevertheless, the authors cautioned that the 
small but measurable QTc impact of aripiprazole may be additive to the 
arrhythmia risk in patients at high risk for torsade de pointes. 
Reversible ECG changes had been reported in a patient who devel-
oped first degree AV block with aripiprazole 45 mg monotherapy. Two 
other patients developed left bundle branch block with concomitant use 
of risperidone and clonezepam, respectively14). A study by Nagamine15), 
identified polypharmacy and high doses of more than 1,000 mg chlor-
promazine equivalent as risk factors among 12 mortality cases related to 
aripiprazole long acting injection in Japan. Therefore, monitoring of 
high risk patient on aripiprazole is important. Of note, this patient had 
history of hypocalcemia in 2014 which may recur in future while the 
patient on aripiprazole.
Recently, it was found that antipsychotics with a high potency for 
the hERG potassium channel blockade, a well-known mechanism 
involved in drug-induced arrhythmia16), had a higher risk of ventricular 
arrhythmia and/or sudden cardiac death, regardless of cardiovascular 
disease status17). A systematic review18) concluded that aripiprazole, 
clozapine, droperidol, mesoridazine, olanzapine, perphenazine, risperi-
done, and thioridazine have evidence of hERG liability. 
Since the patient was previously on combined antipsychotics and 
ECT, it was only logical that aripiprazole should be augmented with 
ECT. The safety of the electroconvulsive therapy-aripiprazole combina-
tion was reported in previous studies19-21). This patient was planned for 
maintenance ECT; however he defaulted after 2 sessions. The use of 
maintenance ECT combined with antipsychotics is a good treatment 
strategy in treatment-resistant psychosis. A recent case report described 
a patient with treatment-resistant psychosis with neurosyphilis who had 
received more than 120 maintenance ECT sessions while receiving 
clozapine22).
CONCLUSION
The combined use of aripiprazole and ECT is safe for treatment of 
treatment-resistant schizophrenia with prolonged QTc. Close monitoring 
is recommended since QTc impact of aripiprazole may be additive to the 
arrhythmia risk.
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